ETR:SAZ - Stada Arzneimittel Stock Price, Price Target & More

€84.00 +0.06 (+0.07 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close€84.00
Today's Range€84.00 - €84.68
52-Week Range€53.41 - €90.24
Volume21,214 shs
Average Volume51,761 shs
Market Capitalization$5.27 billion
P/E RatioN/A
Dividend Yield0.13%
BetaN/A

About Stada Arzneimittel (ETR:SAZ)

Stada Arzneimittel logoSTADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.

Receive SAZ News and Ratings via Email

Sign-up to receive the latest news and ratings for SAZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolETR:SAZ
CUSIPN/A
Phone+49-6101-6030

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins3.48%
Return on Equity7.58%
Return on Assets2.27%

Miscellaneous

EmployeesN/A
Outstanding Shares62,260,000

How to Become a New Pot Stock Millionaire

Stada Arzneimittel (ETR:SAZ) Frequently Asked Questions

What is Stada Arzneimittel's stock symbol?

Stada Arzneimittel trades on the ETR under the ticker symbol "SAZ."

What price target have analysts set for SAZ?

7 equities research analysts have issued 12-month target prices for Stada Arzneimittel's shares. Their forecasts range from €66.00 to €89.00. On average, they expect Stada Arzneimittel's stock price to reach €73.49 in the next twelve months. View Analyst Ratings for Stada Arzneimittel.

Who are some of Stada Arzneimittel's key competitors?

Who are Stada Arzneimittel's key executives?

Stada Arzneimittel's management team includes the folowing people:
  • Dr. Claudio Albrecht, Chairman of the Exec. Board & CEO (Age 59)
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)
  • Dr. Barthold Piening, Chief Technical Operations Officer & Member of Exec. Board (Age 60)
  • Ms. Leslie Isabelle Iltgen, VP of Investor Relations
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43)

Has Stada Arzneimittel been receiving favorable news coverage?

News headlines about SAZ stock have been trending positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Stada Arzneimittel earned a coverage optimism score of 0.41 on Accern's scale. They also gave news coverage about the company an impact score of 45.77 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

What is Stada Arzneimittel's stock price today?

One share of SAZ stock can currently be purchased for approximately €84.00.

How big of a company is Stada Arzneimittel?

Stada Arzneimittel has a market capitalization of $5.27 billion.

How can I contact Stada Arzneimittel?

Stada Arzneimittel's mailing address is Stadastrasse 2-18, BAD VILBEL, 61118, Germany. The company can be reached via phone at +49-6101-6030.


MarketBeat Community Rating for Stada Arzneimittel (SAZ)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Stada Arzneimittel and other stocks. Vote "Outperform" if you believe SAZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAZ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Stada Arzneimittel (ETR:SAZ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Stada Arzneimittel in the last 12 months. Their average twelve-month price target is €73.49The high price target for SAZ is €89.00 and the low price target for SAZ is €66.00. There are currently 5 sell ratings and 2 hold ratings for the stock, resulting in a consensus rating of "Sell."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: SellSellSellSell
Consensus Rating Score: 1.291.291.331.33
Ratings Breakdown: 5 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €73.49€73.49€74.08€69.07

Stada Arzneimittel (ETR:SAZ) Consensus Price Target History

Price Target History for Stada Arzneimittel (ETR:SAZ)

Stada Arzneimittel (ETR:SAZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/4/2018Warburg ResearchSet Price TargetSell€74.40View Rating Details
4/4/2018Independent ResearchSet Price TargetNeutral€89.00View Rating Details
3/23/2018Nord/LBSet Price TargetSell€74.40View Rating Details
3/12/2018CfraSet Price TargetSell€70.00View Rating Details
12/26/2017CommerzbankSet Price TargetSell€66.25View Rating Details
11/10/2017S&P GlobalSet Price TargetSell€74.40View Rating Details
7/11/2017Kepler Capital MarketsSet Price TargetNeutral€66.00View Rating Details
(Data available from 4/21/2016 forward)

Earnings

Dividends

Stada Arzneimittel (ETR:SAZ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Stada Arzneimittel (ETR SAZ) Insider Trading and Institutional Ownership History

Insider Trading History for Stada Arzneimittel (ETR:SAZ)

Stada Arzneimittel (ETR SAZ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Stada Arzneimittel (ETR SAZ) News Headlines

Source:
DateHeadline
Stada Arzneimittel (SAZ) Given a €66.00 Price Target by Commerzbank AnalystsStada Arzneimittel (SAZ) Given a €66.00 Price Target by Commerzbank Analysts
www.americanbankingnews.com - April 20 at 4:16 PM
Kepler Capital Markets Reiterates "€58.00" Price Target for Stada Arzneimittel (SAZ)Kepler Capital Markets Reiterates "€58.00" Price Target for Stada Arzneimittel (SAZ)
www.americanbankingnews.com - April 20 at 11:19 AM
Stada Arzneimittel (SAZ) PT Set at €66.25 by S&P GlobalStada Arzneimittel (SAZ) PT Set at €66.25 by S&P Global
www.americanbankingnews.com - April 19 at 3:34 PM
Stada Arzneimittel (SAZ) Given a €66.25 Price Target at S&P GlobalStada Arzneimittel (SAZ) Given a €66.25 Price Target at S&P Global
www.americanbankingnews.com - April 13 at 6:39 PM
Stada Arzneimittel (SAZ) Given Consensus Recommendation of "Sell" by AnalystsStada Arzneimittel (SAZ) Given Consensus Recommendation of "Sell" by Analysts
www.americanbankingnews.com - April 13 at 1:41 AM
Stada Arzneimittel (SAZ) Given a €66.25 Price Target by Independent Research AnalystsStada Arzneimittel (SAZ) Given a €66.25 Price Target by Independent Research Analysts
www.americanbankingnews.com - April 12 at 12:29 AM
Commerzbank Analysts Give Stada Arzneimittel (SAZ) a €66.25 Price TargetCommerzbank Analysts Give Stada Arzneimittel (SAZ) a €66.25 Price Target
www.americanbankingnews.com - April 10 at 9:17 AM
Stada Arzneimittel (SAZ) Given a €74.40 Price Target at Warburg ResearchStada Arzneimittel (SAZ) Given a €74.40 Price Target at Warburg Research
www.americanbankingnews.com - April 9 at 1:23 PM
Independent Research Analysts Give Stada Arzneimittel (SAZ) a €89.00 Price TargetIndependent Research Analysts Give Stada Arzneimittel (SAZ) a €89.00 Price Target
www.americanbankingnews.com - April 4 at 11:54 AM
Warburg Research Reiterates "€74.40" Price Target for Stada Arzneimittel (SAZ)Warburg Research Reiterates "€74.40" Price Target for Stada Arzneimittel (SAZ)
www.americanbankingnews.com - April 4 at 11:45 AM
What Should We Expect From STADA Arzneimittel Aktiengesellschaft’s (FRA:SAZ) Earnings In The Year Ahead?What Should We Expect From STADA Arzneimittel Aktiengesellschaft’s (FRA:SAZ) Earnings In The Year Ahead?
finance.yahoo.com - March 28 at 10:36 AM
Nord/LB Analysts Give Stada Arzneimittel (SAZ) a €74.40 Price TargetNord/LB Analysts Give Stada Arzneimittel (SAZ) a €74.40 Price Target
www.americanbankingnews.com - March 23 at 6:06 PM
Stada Arzneimittel (SAZ) Given a €89.00 Price Target by Independent Research AnalystsStada Arzneimittel (SAZ) Given a €89.00 Price Target by Independent Research Analysts
www.americanbankingnews.com - March 21 at 10:27 AM
STADA Arzneimittel AG (SAZ) Receives Consensus Rating of "Sell" from AnalystsSTADA Arzneimittel AG (SAZ) Receives Consensus Rating of "Sell" from Analysts
www.americanbankingnews.com - March 19 at 1:52 AM
STADA Arzneimittel (SAZ) Given a €89.00 Price Target at Independent ResearchSTADA Arzneimittel (SAZ) Given a €89.00 Price Target at Independent Research
www.americanbankingnews.com - March 12 at 8:48 PM
STADA Arzneimittel (SAZ) Given a €70.00 Price Target at CfraSTADA Arzneimittel (SAZ) Given a €70.00 Price Target at Cfra
www.americanbankingnews.com - March 12 at 12:20 PM
Stada Arzneimittel AG 2017 Q4 - Results - Earnings Call SlidesStada Arzneimittel AG 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 8 at 4:14 PM
BRIEF-STADA to propose a dividend of 0.11 euros per shareBRIEF-STADA to propose a dividend of 0.11 euros per share
www.reuters.com - March 8 at 11:06 AM
STADA Arzneimittel AG (SAZ) Receives Average Rating of "Sell" from BrokeragesSTADA Arzneimittel AG (SAZ) Receives Average Rating of "Sell" from Brokerages
www.americanbankingnews.com - February 22 at 1:24 AM
Stada Looks East in Expansion PushStada Looks East in Expansion Push
finance.yahoo.com - February 16 at 9:50 AM
STADA Arzneimittel Names Peter Goldschmidt CEO, Succeeding Claudio AlbrechtSTADA Arzneimittel Names Peter Goldschmidt CEO, Succeeding Claudio Albrecht
www.nasdaq.com - February 1 at 8:33 AM
STADA Arzneimittel AG (SAZ) Given Consensus Recommendation of "Sell" by BrokeragesSTADA Arzneimittel AG (SAZ) Given Consensus Recommendation of "Sell" by Brokerages
www.americanbankingnews.com - January 28 at 1:34 AM
STADA Arzneimittel AG (SAZ) Receives Consensus Recommendation of "Sell" from AnalystsSTADA Arzneimittel AG (SAZ) Receives Consensus Recommendation of "Sell" from Analysts
www.americanbankingnews.com - January 3 at 1:58 AM
Nord/LB Reiterates €74.40 Price Target for STADA Arzneimittel (SAZ)Nord/LB Reiterates €74.40 Price Target for STADA Arzneimittel (SAZ)
www.americanbankingnews.com - December 26 at 10:40 AM
STADA Arzneimittel (SAZ) Given a €66.25 Price Target at CommerzbankSTADA Arzneimittel (SAZ) Given a €66.25 Price Target at Commerzbank
www.americanbankingnews.com - December 26 at 8:34 AM
STADA Arzneimittel (SAZ) PT Set at €74.40 by Nord/LBSTADA Arzneimittel (SAZ) PT Set at €74.40 by Nord/LB
www.americanbankingnews.com - December 20 at 10:00 AM
STADA Arzneimittel (SAZ) PT Set at €74.40 by Warburg ResearchSTADA Arzneimittel (SAZ) PT Set at €74.40 by Warburg Research
www.americanbankingnews.com - December 20 at 8:52 AM
BRIEF-Stada Says Domination And Profit And Loss Transfer Agreement ConcludedBRIEF-Stada Says Domination And Profit And Loss Transfer Agreement Concluded
www.reuters.com - December 19 at 5:45 PM
STADA Arzneimittel Aktiengesellschaft (SAZ) Given Consensus Rating of "Sell" by BrokeragesSTADA Arzneimittel Aktiengesellschaft (SAZ) Given Consensus Rating of "Sell" by Brokerages
www.americanbankingnews.com - December 9 at 1:48 AM
STADA Arzneimittel Aktiengesellschaft (SAZ) Given a €74.40 Price Target at Nord/LBSTADA Arzneimittel Aktiengesellschaft (SAZ) Given a €74.40 Price Target at Nord/LB
www.americanbankingnews.com - November 29 at 10:48 AM
STADA Arzneimittel Aktiengesellschaft (SAZ) Given Average Rating of "Sell" by BrokeragesSTADA Arzneimittel Aktiengesellschaft (SAZ) Given Average Rating of "Sell" by Brokerages
www.americanbankingnews.com - November 14 at 1:50 AM
STADA Arzneimittel AG (SAZ) Given a €74.40 Price Target at Warburg ResearchSTADA Arzneimittel AG (SAZ) Given a €74.40 Price Target at Warburg Research
www.americanbankingnews.com - November 10 at 11:24 AM
STADA Arzneimittel AG (SAZ) Given a €74.40 Price Target by S&P Global AnalystsSTADA Arzneimittel AG (SAZ) Given a €74.40 Price Target by S&P Global Analysts
www.americanbankingnews.com - November 10 at 11:24 AM
Independent Research GmbH Analysts Give STADA Arzneimittel AG (SAZ) a €82.00 Price TargetIndependent Research GmbH Analysts Give STADA Arzneimittel AG (SAZ) a €82.00 Price Target
www.americanbankingnews.com - November 10 at 11:24 AM
STADA Arzneimittel Q3 Profit Rises; Says Well On Track To Achieve 2017 TargetsSTADA Arzneimittel Q3 Profit Rises; Says Well On Track To Achieve 2017 Targets
www.rttnews.com - November 9 at 3:16 PM
Stada Arzneimittel AG 2017 Q3 - Results - Earnings Call SlidesStada Arzneimittel AG 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 9 at 3:16 PM
STADA Arzneimittel AG (SAZ) Receives Average Recommendation of "Sell" from AnalystsSTADA Arzneimittel AG (SAZ) Receives Average Recommendation of "Sell" from Analysts
www.americanbankingnews.com - October 20 at 2:48 AM
Stada's CEO Says Top Line Growth Moved by New ProductsStada's CEO Says Top Line Growth Moved by New Products
finance.yahoo.com - October 6 at 8:42 AM
STADA Arzneimittel Appoints Claudio Albrecht As CEO, With Immediate EffectSTADA Arzneimittel Appoints Claudio Albrecht As CEO, With Immediate Effect
www.rttnews.com - September 28 at 2:39 AM
BRIEF-Stada says elects Guenter von Au as new chairmanBRIEF-Stada says elects Guenter von Au as new chairman
www.reuters.com - September 27 at 4:36 PM
STADA Arzneimittel Elects Günter Von Au As ChairmanSTADA Arzneimittel Elects Günter Von Au As Chairman
www.rttnews.com - September 27 at 4:36 PM
CVC Explores Options For $4 Bln Worth Alvogen: BloombergCVC Explores Options For $4 Bln Worth Alvogen: Bloomberg
www.rttnews.com - September 26 at 11:34 AM
Booming European Loan Market Tops 2016 on Chunky M&A DealsBooming European Loan Market Tops 2016 on Chunky M&A Deals
finance.yahoo.com - September 26 at 11:34 AM
STADA Arzneimittel AG (SAZ) Given Consensus Rating of "Sell" by BrokeragesSTADA Arzneimittel AG (SAZ) Given Consensus Rating of "Sell" by Brokerages
www.americanbankingnews.com - September 25 at 2:38 AM
DGAP-News: Nidda Healthcare Holding AG (deutsch)DGAP-News: Nidda Healthcare Holding AG (deutsch)
www.finanznachrichten.de - September 24 at 7:40 AM
[$$] Giant Bond Issued to Finance Stada Deal[$$] Giant Bond Issued to Finance Stada Deal
finance.yahoo.com - September 23 at 5:14 AM
[$$] Aggressive term in Stada bond sale causes outcry[$$] Aggressive term in Stada bond sale causes outcry
finance.yahoo.com - September 20 at 8:45 AM
STADA Arzneimittel AG (SAZ) Given a €76.00 Price Target by Independent Research GmbH AnalystsSTADA Arzneimittel AG (SAZ) Given a €76.00 Price Target by Independent Research GmbH Analysts
www.americanbankingnews.com - September 5 at 8:26 AM
Bain, Cinven give in to Elliotts demand for higher Stada buyoutBain, Cinven give in to Elliott's demand for higher Stada buyout
finance.yahoo.com - September 4 at 6:28 AM
[$$] Elliott seeks premium to back takeover of Stada[$$] Elliott seeks premium to back takeover of Stada
finance.yahoo.com - September 1 at 8:20 AM

SEC Filings

Stada Arzneimittel (ETR:SAZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Stada Arzneimittel (ETR SAZ) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.